Health and Healthcare

AbbVie : ABBV

All AbbVie Articles

587 Articles

Chris Lange | Sep 13, 2017 at 8:40 AM EDT

Major Pharma Short Interest Surges

The August 31 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Sep 7, 2017 at 4:08 PM EDT

Thursday’s Biggest Winners and Losers in the S&P 500

Thursday was a mixed day for the U.S. broad markets with all major indices starting off positive, but quickly souring…

Chris Lange | Aug 25, 2017 at 9:55 AM EDT

Short Sellers Run for Cover From Major Pharma

The August 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Aug 10, 2017 at 8:40 AM EDT

Short Sellers Hike Bets in Major Pharma

The July 31 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Aug 2, 2017 at 1:20 PM EDT

Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease

A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its…

Chris Lange | Jul 28, 2017 at 11:10 AM EDT

AbbVie Slips Despite Q2 Earnings Beat

AbbVie reported better-than-expected second-quarter financial results before the markets opened on Friday.

Chris Lange | Jul 26, 2017 at 8:55 AM EDT

Major Pharma Short Interest Takes a Big Step Back

The July 14 short interest data have been compared with the previous figures, and short interest in most of these…

Lee Jackson | Jul 19, 2017 at 9:42 AM EDT

SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017

A new report from SunTrust Robinson Humphrey indicates big pharmaceuticals may be the place to be for investors. Among the…

Chris Lange | Jul 13, 2017 at 9:20 AM EDT

Major Pharma Short Sellers Become More Selective

The June 30 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Jun 27, 2017 at 8:45 AM EDT

Short Sellers Run for Cover From Major Pharma

The June 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jun 12, 2017 at 8:55 AM EDT

Short Sellers Grow More Selective on Major Pharma

The May 31 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Jun 2, 2017 at 1:35 PM EDT

15 Companies Bracing for Big ASCO Reactions

24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could…

Chris Lange | May 27, 2017 at 8:40 AM EDT

Big Pharma Has Big Catalysts Coming for the Rest of 2017

A new Deutsche Bank research report focuses on the big capitalization pharmaceutical stocks and the upcoming catalysts and news flow…

Chris Lange | May 25, 2017 at 9:45 AM EDT

Major Pharma Short Interest Surges

The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

1 … 23 24 25 26 27 … 40

AbbVie : ABBV

All AbbVie Articles

Major Pharma Short Interest Surges

Thursday’s Biggest Winners and Losers in the S&P 500

Short Sellers Run for Cover From Major Pharma

Short Sellers Hike Bets in Major Pharma

Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease

AbbVie Slips Despite Q2 Earnings Beat

Major Pharma Short Interest Takes a Big Step Back

SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017

Major Pharma Short Sellers Become More Selective

Short Sellers Run for Cover From Major Pharma

Short Sellers Grow More Selective on Major Pharma

15 Companies Bracing for Big ASCO Reactions

Top Presentations to Look for at ASCO

Big Pharma Has Big Catalysts Coming for the Rest of 2017

Major Pharma Short Interest Surges

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

Forget the Labor Market Noise: This Essential Business Utility Stock Is the Ultimate “Set-It-and-Forget-It” Cash Cow

3 Stocks With a Yield Over 6% For Passive Income Investors

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

A $2.5 Million 401(k) at 73 Can Still Cost You Six Figures Without These 3 Moves

A Covered Call ETF That Pays 6% Is Beating Vanguard’s Biggest International ETF Right Now

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

AbbVie : ABBV

All AbbVie Articles

Major Pharma Short Interest Surges

Thursday’s Biggest Winners and Losers in the S&P 500

Short Sellers Run for Cover From Major Pharma

Short Sellers Hike Bets in Major Pharma

Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease

AbbVie Slips Despite Q2 Earnings Beat

Major Pharma Short Interest Takes a Big Step Back

SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017

Major Pharma Short Sellers Become More Selective

Short Sellers Run for Cover From Major Pharma

Short Sellers Grow More Selective on Major Pharma

15 Companies Bracing for Big ASCO Reactions

Top Presentations to Look for at ASCO

Big Pharma Has Big Catalysts Coming for the Rest of 2017

Major Pharma Short Interest Surges

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

Forget the Labor Market Noise: This Essential Business Utility Stock Is the Ultimate “Set-It-and-Forget-It” Cash Cow

3 Stocks With a Yield Over 6% For Passive Income Investors

Featured Reads

Suze Orman to 54-Year-Old With $600,000: Skip the 1.5% Fee and Manage It Yourself

A $2.5 Million 401(k) at 73 Can Still Cost You Six Figures Without These 3 Moves